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RESEARCH
Home and Online Management and Evaluation of Blood  
Pressure (HOME BP) using a digital intervention in poorly  
controlled hypertension: randomised controlled trial
Richard J McManus,1 Paul Little,2 Beth Stuart,2 Katherine Morton,3 James Raftery,2 Jo Kelly,2 
Katherine Bradbury,3 Jin Zhang,3 Shihua Zhu,2 Elizabeth Murray,4 Carl R May,5 Frances S Mair,6 
Susan Michie,7 Peter Smith,2 Rebecca Band,3 Emma Ogburn,1 Julie Allen,1 Cathy Rice,8  
Jacqui Nuttall,9 Bryan Williams,10 Lucy Yardley,3,11 on behalf of the HOME BP investigators
AbstrAct
Objective
The HOME BP (Home and Online Management and 
Evaluation of Blood Pressure) trial aimed to test a 
digital intervention for hypertension management in 
primary care by combining self-monitoring of blood 
pressure with guided self-management.
Design
Unmasked randomised controlled trial with automated 
ascertainment of primary endpoint.
setting
76 general practices in the United Kingdom.
ParticiPants
622 people with treated but poorly controlled 
hypertension (>140/90 mm Hg) and access to the 
internet.
interventiOns
Participants were randomised by using a minimisation 
algorithm to self-monitoring of blood pressure with 
a digital intervention (305 participants) or usual 
care (routine hypertension care, with appointments 
and drug changes made at the discretion of the 
general practitioner; 317 participants). The digital 
intervention provided feedback of blood pressure 
results to patients and professionals with optional 
lifestyle advice and motivational support. Target blood 
pressure for hypertension, diabetes, and people aged 
80 or older followed UK national guidelines.
Main OutcOMe Measures
The primary outcome was the difference in systolic 
blood pressure (mean of second and third readings) 
after one year, adjusted for baseline blood pressure, 
blood pressure target, age, and practice, with multiple 
imputation for missing values.
results
After one year, data were available from 552 
participants (88.6%) with imputation for the 
remaining 70 participants (11.4%). Mean blood 
pressure dropped from 151.7/86.4 to 138.4/80.2 
mm Hg in the intervention group and from 151.6/85.3 
to 141.8/79.8 mm Hg in the usual care group, giving 
a mean difference in systolic blood pressure of 
−3.4 mm Hg (95% confidence interval −6.1 to −0.8 
mm Hg) and a mean difference in diastolic blood 
pressure of −0.5 mm Hg (−1.9 to 0.9 mm Hg). Results 
were comparable in the complete case analysis and 
adverse effects were similar between groups. Within 
trial costs showed an incremental cost effectiveness 
ratio of £11 ($15, €12; 95% confidence interval £6 to 
£29) per mm Hg reduction.
cOnclusiOns
The HOME BP digital intervention for the management 
of hypertension by using self-monitored blood 
pressure led to better control of systolic blood 
pressure after one year than usual care, with low 
incremental costs. Implementation in primary care 
will require integration into clinical workflows and 




Hypertension is the major risk factor for cardiovascular 
disease internationally and evidence from several 
randomised controlled trials shows that this risk 
can be reduced by lowering blood pressure.1 2 In the 
United Kingdom, almost 30% of adults have raised 
blood pressure (≥140/90 mm Hg), with the proportion 
increasing to more than 50% in people aged 65 and 
older.3 Target blood pressure levels are reached for less 
than half of adults, and with an ageing population, 
novel interventions are required to improve blood 
pressure control.3 4
Digital interventions (apps, programmes, or software 
used in a health context) have the potential to support 
people in self-management.4 5 A digital intervention 
developed by our group that facilitates lifestyle change 
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WhAt Is AlreAdy knoWn on thIs topIc
Previous trials of self-monitoring and self-management have shown effectiveness 
in reducing blood pressure, but have often relied on relatively expensive 
technology or time consuming training packages to realise any benefit
Short term trials of digital interventions have shown potential to improve blood 
pressure control, but have not provided sufficient evidence for widespread 
implementation
WhAt thIs study Adds
Home and Online Management and Evaluation of Blood Pressure (HOME BP) is a 
digital intervention comprising self-monitoring of blood pressure with reminders 
and predetermined drug changes combined with lifestyle change support for the 
self-management of high blood pressure 
HOME BP resulted in better control of systolic blood pressure after one year than 
usual care and at low incremental cost; adverse events were similar to usual care
Digital interventions such as HOME BP have the potential to be implemented at 
scale in a cost effective manner
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in primary care patients with obesity resulted in cost 
effective weight loss.6 However, for patients with 
hypertension, evidence for digital interventions has 
been from small trials with relatively short follow-
up and substantial heterogeneity of results.7 One 
trial that lasted longer than 10 months reported that 
patients’ blood pressure was not reduced.8 We have 
previously shown that self-monitoring combined with 
self-titration of antihypertensive drugs is cost effective 
and leads to considerably lower blood pressure in 
people with essential hypertension and those at 
higher risk. However, this approach requires extensive 
manual record keeping, which makes implementation 
difficult.9-12 Therefore, a digital intervention that 
combines our previous knowledge of self-management 
of hypertension with digital support and lifestyle 
changes might result in lower blood pressure with 
associated lifestyle changes, including weight 
management. This intervention could be more easily 
integrated into clinical care by patients and healthcare 
professionals, and would allow remote monitoring, an 
important consideration when people are restricted to 
staying home because of disability or to avoid exposure 
to infection. Clinical monitoring of these patients 
would be difficult or impossible.13
The HOME BP trial aimed to evaluate whether a 
digital intervention comprising self-monitoring of 
blood pressure with reminders and predetermined 
drug changes combined with lifestyle change support 
resulted in lower systolic blood pressure in people 
receiving treatment for hypertension that was poorly 
controlled, and whether this approach was cost 
effective.
Methods
The methods of the HOME BP trial have already been 
described in detail.14 Briefly, it was an unmasked 
randomised controlled trial with automated ascer-
tainment of outcome. The study compared a digital 
intervention for hypertension management and 
self-monitoring of blood pressure with usual care 
(routine hypertension care, with appointments and 
drug changes made at the discretion of the general 
practitioner).
Population
Eligible participants were aged 18 or older with treated 
hypertension, a mean baseline blood pressure reading 
(calculated from the second and third blood pressure 
readings) of more than 140/90 mm Hg, and were 
taking no more than three antihypertensive drugs. 
For the digital intervention, participants needed to be 
willing to self-monitor and have access to the internet 
(with support from a family member if needed).
Exclusions included blood pressure greater than 
180/110 mm Hg, atrial fibrillation, hypertension not 
managed by their general practitioner, chronic kidney 
disease stage 4-5, postural hypotension (>20 mm Hg 
systolic drop), an acute cardiovascular event in the 
previous three months, terminal disease, or another 
condition which in the opinion of their general 
practitioner made participation inappropriate.
Procedure
We used practices from the National Institute for Health 
Research Clinical Research Network (https://www.
nihr.ac.uk/explore-nihr/support/clinical-research-
network.htm). Eligible people were identified from 
clinical codes recorded in the electronic health records 
of collaborating general practices; these people were 
invited to attend a baseline clinic to learn about 
the study. At the clinic, eligibility was established, 
informed consent was obtained from people who 
wished to participate, and their baseline clinical 
data were collected. People who did not want to take 
part in the trial were given the option to complete a 
form giving their reasons. Study nurses measured 
participants’ blood pressure after five minutes’ rest 
using a standardised technique with a validated 
electronic automated sphygmomanometer (BP TRU 
BPM 200).15 Six blood pressure readings were taken 
at intervals of one minute. All participants completed 
online questionnaires.
Eligible participants were randomised using an 
online system (https://www.lifeguideonline.org) 
in a 1:1 ratio to receive usual care or the HOME BP 
intervention with optional nurse support. Minimisation 
factors were participants’ baseline systolic blood 
pressure, age, diabetes status, and practice. Practice 
staff were notified of patient group allocation by email.
After randomisation, all patients received a blood 
pressure drug review from a general practitioner or 
nurse prescriber (prescribers). For patients allocated 
to the intervention group, prescribers were asked 
to select and agree an individualised drug titration 
plan (including three potential drug changes if blood 
pressure remained above target).10 Participating 
clinicians were given information about the National 
Institute for Health and Care Excellence (NICE) 
guidance within the HOME BP intervention but were 
not asked to follow set algorithms for drugs.
Six and 12 months after randomisation, participants 
attended follow-up appointments with an independent 
research nurse where blood pressure and weight were 
recorded (weight was recorded at 12 months only). 
Participants then completed follow-up questionnaires 
online.
intervention
The HOME BP intervention for the self-management of 
high blood pressure consisted of an integrated patient 
and healthcare practitioner online digital intervention, 
blood pressure self-monitoring, healthcare practitioner 
directed and supervised titration of antihypertensive 
drugs, and user selected lifestyle modifications. The 
intervention was developed using a theory, evidence, 
and person based approach16 that was designed to 
influence the behaviour of participants and healthcare 
professionals. The development process has been fully 
described elsewhere; briefly, it comprised an iterative 
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process including think aloud interviews to provide 
detailed feedback on the HOME BP prototype.17-19
Participants were given online instructions on 
how to correctly undertake self-monitoring (using an 
Omron M3 monitor), with a demonstration video.20 
Participants were then asked to rehearse self-
monitoring for a minimum of seven days and enter 
these initial readings into HOME BP online before 
undertaking study procedures.
Participants were advised, with automated email 
reminders, to take two morning blood pressure 
readings for seven days each month and to enter online 
each second reading (following methods used in the 
TASMINH2 and TASMIN-SR studies).21  22 Mean home 
blood pressure was then calculated and feedback 
provided to the participants and the healthcare 
practitioners by using a traffic light system (developed 
from the system used in previous drug titration 
procedures).21 22 When mean home blood pressure was 
above target for two consecutive months, the prescriber 
was asked by email to implement the preplanned drug 
change.
The following home blood pressure targets were set 
in line with up-to-date NICE hypertension guidelines23; 
an adjustment of 5/5 mm Hg was made for home 
readings24:
•	 People younger than 80 without diabetes: less 
than 135/85 mm Hg
•	 People aged 80 and over without diabetes: less 
than 145/85 mm Hg
•	 People with diabetes: less than 135/75 mm Hg.
When home blood pressure readings were very 
high (>180/110 mm Hg) or very low (systolic blood 
pressure <100 mm Hg), patients were advised to call 
their general practitioner within three days and HOME 
BP healthcare practitioners were alerted by email. If 
mean home blood pressure was controlled for three 
consecutive months (defined as 100-134/≤84 mm Hg), 
patients were advised to reduce blood pressure 
monitoring to once every eight weeks; monitoring 
reverted back to every month if mean blood pressure 
subsequently increased above 135/85 mm Hg.
The HOME BP intervention included elements 
designed to motivate and support healthy behaviours. 
Information was presented about the health related 
benefits of self-monitoring, about reducing blood 
pressure through drugs, and addressing common 
patient concerns about the side effects of drugs. 
Nine weeks after participants were allocated to the 
intervention (judged to be sufficient time for self-
monitoring habits to have been implemented), an 
optional tool became available outlining user selected 
evidence based lifestyle modifications that target 
healthy eating, physical activity, losing weight (if 
appropriate), and salt and alcohol reduction.14 The 
health behaviours targeted were chosen based on 
normalisation process theory and took the form of web 
pages and links.17
The HOME BP intervention also aimed to build 
healthcare practitioner motivation, knowledge, 
and skills to reduce clinical inertia.17 This objective 
was achieved by presenting evidence of efficacy 
and addressing concerns about patient titration 
acceptance, the reliability of home blood pressure 
readings, and study procedures.
Optional additional behavioural support for self-
monitoring and lifestyle modifications was available 
to intervention participants through practice nurses 
or healthcare assistants (referred to as supporters) 
by using the CARE (congratulate, ask, reassure, 
encourage) approach.17 This support comprised up 
to six brief face-to-face, telephone, or email contacts 
addressing difficulties associated with self-monitoring 
or lifestyle change, with additional monthly email 
support provided by using prewritten templates.
usual care
Participants allocated to usual care were not provided 
with self-monitoring equipment or the HOME BP 
intervention, but had online access to the information 
provided in a patient leaflet for hypertension (patient.
co.uk; through the same system that delivered the 
online questionnaires). This information comprised 
definitions of hypertension, causes, and brief guidance 
on treatment, including lifestyle changes and drugs. 
These participants received routine hypertension 
care that typically consisted of clinic blood pressure 
monitoring to titrate drugs, with appointments and 
drug changes made at the discretion of the general 
practitioner. Participants were not prevented from 
self-monitoring; data on self-monitoring practices 
were collected at the end of the trial from patients and 
practitioners.
In intervention and usual care groups, decisions 
about patients’ drugs remained at the prescriber’s 
discretion at all times.
Outcomes
The primary outcome of the trial was the difference 
in clinic systolic blood pressure (mean of second and 
third readings) at 12 month follow-up between the 
intervention and usual care groups, adjusting for 
baseline blood pressure, practice, blood pressure 
target levels, and sex. Secondary outcomes (also 
adjusted for baseline and covariates if appropriate) 
included systolic and diastolic blood pressure at six 
and 12 months using second and third blood pressure 
readings, and second to sixth blood pressure readings; 
weight; modified patient enablement instrument 
(patients’ feelings of confidence about understanding 
their illness and their ability to manage, understand, 
and cope with their condition; and general health 
problems that occurred after receiving healthcare)25 26; 
drug adherence (Medication Adherence Rating 
Scale questionnaire)27; health related quality of life 
measured with the EuroQoL-5D-5L28; and side effects 
from the symptoms section of an adjusted illness 
perceptions questionnaire.29
After trial registration, participants and general 
practitioners were asked about use of self-monitoring 
in the usual care group. At the end of the trial a medical 
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record review captured prescription of antihypertensive 
drugs (including any changes) and within trial primary 
healthcare resource use (primary care and secondary 
care, including outpatient and inpatient visits). 
Additional outcomes that will be published elsewhere 
included long term economic modelling and a detailed 
process evaluation.
Power calculation and analysis
A sample size of 244 patients for each group was 
required to have 90% power to detect a difference in 
systolic blood pressure of 5 mm Hg (standard deviation 
17 mm Hg) between the intervention and usual care 
groups based on the findings from the TASMINH-2 
study.22 Allowing for a 15% participant dropout, 287 
participants were required for each group, resulting 
in a total sample size of 574 participants. During the 
trial, we decided to increase the sample size to 610 
to allow for a 20% dropout rate because of concerns 
about higher than expected initial dropout (which later 
proved unfounded).
The principal analysis used raw and adjusted data, 
and was agreed in a statistical analysis plan before 
final data lock (see appendix). The primary analysis 
used general linear modelling to compare systolic 
blood pressure in the intervention and usual care 
groups at follow-up, adjusting for baseline blood 
pressure, practice (as a random effect to take into 
account clustering), blood pressure target levels, 
and sex. Analyses were on an intention-to-treat 
basis and used 100 multiple imputations by chained 
equations for missing data. The imputation model 
included all outcome and stratification variables. 
Sensitivity analyses used complete cases and also 
a repeated measures technique. Planned subgroup 
analyses included blood pressure target groups, older 
versus younger participants (67 as threshold), men 
versus women, lower index of multiple deprivation 
scores versus higher scores, and blood pressure 
better controlled at baseline versus worse controlled 
at baseline (above or below median systolic blood 
pressure). Secondary analyses used similar techniques 
to assess differences between groups. Post hoc we 
decided to present antihypertensive drugs as the 
number of dose changes and drug changes rather 
than as defined daily dose (which combines dose and 
number of drugs) to show the specific type of changes 
more clearly.
A within trial economic analysis estimated cost 
per unit reduction in systolic blood pressure—the 
primary outcome—by using similar adjustments and 
multiple imputation for missing values as described 
in the statistical analysis section. UK National Health 
Service resource use costs included those due to the 
intervention and those due to changes in drugs and use 
of other relevant NHS resources. The following items 
were costed (further details in appendix table A6):
•	 Antihypertensive drugs (by dose and dose 
changes, and any new antihypertensive drugs, 
all by number of days used) from NHS drug tariff 
201830
•	 Primary care contact related to blood pressure (by 
type of staff—general practitioner, practice nurse, 
or healthcare assistant) and type of contact (face to 
face, telephone, email, or text, including clinical 
contacts from supporting the intervention)31
•	 Inpatient admission (by health resource use 
code), outpatient visit, or emergency department 
attendance related to hypertension.32
We used repeated (1000 times) bootstrapping to 
estimate the probability of the intervention being cost 
effective at different levels of willingness to pay per 
unit reduction in blood pressure.
trial registration and approvals
HOME BP is registered as ISRCTN13790648 (https://
doi.org/10.1186/ISRCTN13790648). The original 
registration was for the development and pilot phase, 
which ran into the main trial without change. Except 
for an increase in sample size as documented above, no 
other substantive changes were made to the protocol 
after the start of the trial. The trial registration did not 
specify which blood pressure measurements were to 
be used in the secondary outcomes, but these were 
clarified in the statistical analysis plan before data lock 
as the mean of the second and third measurements, 
and the mean of the second to sixth measurements. 
Post hoc analyses are stated.
Patient and public involvement
Patient and public contributors were involved from 
the outline application stage (Samantha Hall and 
Mark Stafford-Watson). At full application stage 
these contributors were joined by Keith Manship and 
Shelley Mason. Key aspects contributed to were the 
development of the intervention, commenting on 
trial documentation, and taking part in the steering 
group meetings. Cathy Rice joined as a patient and 
public contributor during the trial and has remained 
extensively involved, including optimising many 
patient facing documents and intervention training 
content, authorship of this paper and assisting in 
dissemination. We are immensely grateful for the input 
of all of our public contributors.
results
Of 11 399 invitation letters sent out, 1389 (12%) 
potential participants from 76 general practices 
responded positively and were screened for eligibility. 
Those who declined to take part could optionally 
give their reasons, and responses were gained from 
2426/10 010 (24%). The mean age of those who 
gave a reason for declining was 73 years. The most 
commonly selected responses were not having access 
to the internet (982, 41%), not wanting to be part of a 
research trial (617, 25%), not wanting to participate 
in an internet study (543, 22%), and not wanting to 
change drugs (535, 22%; table A1).
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Of the 1389 screened, 734 were ineligible and 
so were excluded (fig 1). A further 33 did not complete 
baseline measures and randomisation, which left 622 
people who were randomised to the HOME BP inter-
vention or usual care (305 and 317, respectively; pro-
portions are in line with the minimisation algorithm). 
The main reasons for exclusion (denominator 734 
in each case) were blood pressure less than 140/ 
90 mm Hg (652, 89%), postural hypotension (31, 4%), 
not taking antihypertensive drugs (18, 2%), and blood 
pressure too high (>180/110 mm Hg; 16, 2%). Fifteen 
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Did not attend follow-up
Fig 1 | Flowchart of HOMe bP (Home and Online Management and evaluation of blood Pressure) trial. *Partial 
withdrawals withdrew from the intervention but consented to be followed up. †Partial withdrawals in usual care 
consented to passive follow-up
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because their blood pressure was out of range were 
randomised in error (in 10 people blood pressure was 
too high; in five people blood pressure was too low). 
After we discussed the issue with the sponsor and 
with the relevant general practitioners, we decided 
to keep these people in the trial unless they wished 
to withdraw, and they have been included in the 
intention-to-treat analysis.
The groups were well matched, with a mean age of 
66 years and mean baseline clinical blood pressure 
of 151.6/85.3 mm Hg and 151.7/86.4 mm Hg (usual 
care and intervention, respectively; table 1). Most 
participants were white British (94%), just over 
half were men, and time since diagnosis averaged 
around 11 years. The most deprived group accounted 
for 63/622 (10%), with the least deprived group 
accounting for 326/622 (52%).
After 12 months, primary endpoint data were 
available from 271 (89%) participants in the 
intervention group and 282 (89%) in the usual care 
group (fig 1). Clinic blood pressure dropped from 
151.7/86.4 to 138.4/80.2 mm Hg in the intervention 
group after 12 months, and from 151.6/85.3 to 
141.8/79.8 mm Hg in the usual care group; this gave 
a mean difference of −3.4 mm Hg (95% confidence 
interval −6.1 to −0.8) in systolic blood pressure and 
−0.5 mm Hg (−1.9 to 0.9) in diastolic blood pressure 
(table 2). The results were similar in the complete case 
analysis and showed a smaller but still significant 
effect size when considering the mean of the second 
to sixth blood pressure readings (table A2). Similarly, 
considering the primary outcome data as repeated 
measures over the 12 months and controlling for 
baseline, a significant difference remained between 
table 1 | baseline characteristics of usual care and intervention groups in the HOMe bP trial. Data are numbers 
(percentages) unless stated otherwise
baseline characteristics usual care (n=317) intervention (n=305)
Age, years (mean (standard deviation)) 66.7 (10.2) 65.2 (10.3)
Systolic blood pressure (mean (standard deviation)) 151.6 (11.1) 151.7 (11.8)
Diastolic blood pressure (mean (standard deviation)) 85.3 (9.9) 86.4 (9.6)
Female 143/318 (45.0) 145/305 (47.5)
Ethnicity
 White 299/317 (94.3) 285/304 (93.8)
 Black African 3/317 (1.0) 5/304 (1.6)
 Black Caribbean 1/317 (0.3) 0/304 (0.0)
 Indian 0/317 (0.0) 3/304 (1.0)
 Pakistani 3/317 (1.0) 1/304 (0.3)
 Other 11/317 (3.5) 10/304 (3.3)
Index of multiple deprivation
 1-3 (most deprived) 27/318 (8.5) 36/304 (11.8)
 4-7 125/318 (39.3) 108/304 (35.5)
 8-10 (least deprived) 166/318 (52.2) 160/304 (52.6)
Marital status
 Married or cohabiting 244/318 (76.7) 240/302 (79.5)
 Single, divorced, or widowed 74/318 (23.3) 62/302 (20.5)
Duration of hypertension, years (mean (standard deviation)) 10.9 (9.4) 11.3 (9.8)
Past medical history
 Diabetes 32/291 (11.0) 24/278 (8.6)
  Type 1 1/291 (0.3) 1/278 (0.4)
 Chronic kidney disease 26/291 (8.9) 22/279 (7.9)
 Stroke 3/292 (1.0) 2/278 (0.7)
 Myocardial infarction 4/291 (1.4) 7/278 (2.5)
 Coronary artery bypass graft, angioplasty, or stent 3/292 (1.0) 10/278 (3.6)
 Other comorbid condition 67/288 (23.2) 70/273 (25.6)
Body mass index (mean (standard deviation)) 29.6 (5.4) 30.2 (6.6)
No of antihypertensive drugs at baseline (median (interquartile range)) 1 (1-2) 1 (1-2)
HOME BP=Home and Online Management and Evaluation of Blood Pressure.
table 2 | Mean (standard deviation) blood pressure at baseline, six months, and 12 months using second and third measurements, and adjusted 
difference
blood pressure baseline 6 months 12 months
imputed (100 imputations) complete cases
adjusted difference 
at 6 months*






systolic blood pressure (mm Hg)†
Usual care 151.6 (11.1) 140.9 (16.0) 141.8 (16.8) — — — —
Intervention 151.7 (11.8) 138.7 (17.0) 138.4 (16.0) −2.3 (−4.9 to 0.3) −3.4 (−6.1 to −0.8) −2.3 (−4.8 to 0.3) −3.5 (−6.2 to −0.9)
Diastolic blood pressure (mm Hg)
Usual care 85.3 (9.9) 80.2 (10.3) 79.8 (10.1) — — — —
Intervention 86.4 (9.6) 79.9 (9.7) 80.2 (10.1) −1.0 (−2.4 to 0.4) −0.5 (−1.9 to 0.9) −1.0 (−2.4 to 0.3) −0.5 (−1.8 to 0.9)
*Mean difference (95% confidence interval) controlling for baseline blood pressure, age, sex, and blood pressure target, with a random effect for practice.
†Systolic blood pressure at 12 months was the primary outcome.
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groups in favour of the HOME BP intervention: −2.9 mm 
Hg (95% confidence interval −4.8 to −1.1 mm Hg) 
for systolic blood pressure and −0.6 mm Hg (−1.6 to 
0.5 mm Hg) for diastolic blood pressure.
A post hoc analysis showed that blood pressure 
dropped by at least 5 mm Hg in 201/270 (74.4%) 
of the intervention group compared with 170/282 
(60.3%) of those receiving usual care: adjusted odds 
ratio for a 5 mm Hg drop: 1.9 (95% confidence interval 
1.3 to 2.8; controlling for practice level clustering and 
stratification factors).
Exploratory subgroup analyses (fig 2, table A3) 
suggested that participants aged 67 or older had a 
smaller effect size (−0.4 mm Hg, 95% confidence 
interval −3.9 to 3.0 mm Hg) than those younger than 67 
(−7.7 mm Hg, −11.9 to −3.5 mm Hg). Similarly, while 
the effect sizes in the standard and diabetes target 
groups were similar (−4.0 mm Hg, −6.9 to −1.1 mm Hg; 
−3.8 mm Hg, −13.4 to 5.8 mm Hg, respectively), those 
older than 80 years with a higher target of 145/85 
mm Hg showed little evidence of benefit (1.5 mm Hg, 
−7.4 to 10.4 mm Hg). Results for other subgroups, 
including sex, baseline blood pressure, deprivation, 
and history of self-monitoring, were similar between 
groups; however, it is possible that those with 
comorbidities gained less from the intervention 
(systolic blood pressure difference, controlled for age—
no comorbidity: −5.1 mm Hg, −8.4 to −1.8 mm Hg; one 
comorbidity: −0.6 mm Hg, −5.8 to 4.5 mm Hg; multiple 
comorbidities: −2.0 mm Hg, −11.1 to 7.2 mm Hg).
Information about possible adverse effects was 
derived from an extended version of the illness 
perceptions questionnaire symptoms section and 
showed no differences between groups29 (table 3). More 
participants in the intervention group reported weight 
loss (29/243, 11.9% v 57/251, 22.7%; P=0.002), but 
this was not borne out by the objective weight data 
(mean difference −0.36 kg, 95% confidence interval 
−1.10 to 0.38 kg; table A4).
Participants who used the digital intervention 
were more likely to have their antihypertensive drugs 
adjusted during the study; this included more changes 
in dose (relative risk of a dose change, intervention v 
usual care: 2.0, 95% confidence interval 1.5 to 2.7) 
and more changes in drugs (relative risk of a drug 
change, intervention v usual care: 1.5, 1.1 to 1.9; 
table 4). Self-reported adherence in both groups was 
high throughout (Medication Adherence Rating Scale 
questionnaire27: median baseline 24, maximum 
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Fig 2 | exploratory subgroup analyses showing effect sizes in usual care and intervention groups. iMD=index of 
multiple deprivation (lower score means less deprived)
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24, interquartile range 23-25 in the control group, 
and 24, interquartile range 24-25 in the intervention 
group; P=0.97 for the difference).
Engagement with the digital intervention was high, 
with 281/305 (92%) participants completing the two 
core training sessions, 268/305 (88%) completing a 
week of practice blood pressure readings, and 243/305 
(80%) completing at least three weeks of blood 
pressure entries (table A5). Furthermore, 214/305 
(70%) were still monitoring in the last three months of 
participation (of 12 month study). However, less than 
one third of participants chose to register on one of the 
optional lifestyle change modules. Of the subsample 
of 243 participants with a body mass index greater 
than 25, 46 (19%) registered on the online weight loss 
programme.
The patient enablement score showed a reduction 
over time (that is, increased enablement) in the self-
management group. This reduction meant that by 12 
months a significant difference was found (−0.4, 95% 
confidence interval −0.5 to −0.2) between the usual 
care and intervention groups (table 5).
After 12 months, a post hoc analysis showed that 
112/234 (47%) patients in the usual care group 
reported monitoring their own blood pressure at home 
at least once per month during the trial; of these, 78 
(70%) said that they took their readings to their general 
practitioner. Of 56/76 (74%) general practitioners who 
responded, 35 (63%) reported using home readings in 
their titration decisions for usual care.
The within trial analysis for quality of life (EuroQoL-
5D-5L) showed no significant difference between 
the two groups (table 6). The difference in mean cost 
per patient was £38 ($51.3, €41.9; 95% confidence 
interval £27 to £47), which along with the decrease in 
systolic blood pressure, gave an incremental cost per 
mm Hg blood pressure reduction of £11 (£6 to £29; 
table 7). Figure A1 shows the results of bootstrapping 
the incremental cost and blood pressure gains, which 
are summarised in the cost effectiveness acceptability 
curves (fig A2). These curves show the intervention 
had high (90%) probability of being cost effective at 
willingness to pay above £20 per unit reduction. The 
probabilities of being cost effective for the intervention 
against usual care were 87%, 93%, and 97% at 
thresholds of £20, £30, and £50, respectively.
discussion
Main findings
A digital intervention enabling self-management of 
hypertension, including self-monitoring, titration 
based on self-monitored blood pressure, lifestyle 
advice, and behavioural support for patients and 
healthcare professionals, resulted in a worthwhile 
reduction of systolic blood pressure achieved at modest 
cost. This finding was robust in sensitivity analyses, 
including complete case analysis, and also when the 
mean of the second to sixth blood pressure readings 
was used as the outcome. The reduction was achieved 
through increased titration of antihypertensive drugs 
with no increase in adverse effects, suggesting that the 
HOME BP digital intervention reduces clinical inertia 
and leads to optimisation of treatment. The effect size 
observed from this intervention could be expected to 
result in a reduction of 10-15% in patients having a 
stroke and a reduction of 5-10% in patients having 
coronary events. Given the low marginal cost, such an 
effect could make a major difference to the millions of 
table 3 | Participants who reported a hypertension drug specific symptom or adverse 
effect at final follow-up. Data are numbers (percentages)
reported symptoms control intervention
P value for 
difference
general symptoms
Stiff joints 140/252 (55.6) 138/243 (56.8) 0.92
Pain 118/252 (46.8) 116/244 (47.5) 0.40
Sleep difficulties 129/252 (51.2) 111/243 (45.7) 0.54
Fatigue 109/252 (43.3) 112/242 (46.3) 0.15
Cough 94/251 (37.5) 85/246 (34.6) 0.75
Loss of strength 62/251 (24.7) 75/244 (30.7) 0.19
Sore eyes 62/251 (24.7) 71/244 (29.1) 0.86
Pins and needles 69/250 (27.6) 71/246 (28.9) 0.92
Loss of libido 59/249 (23.7) 63/238 (26.5) 0.55
Headaches 72/251 (28.7) 64/245 (26.1) 0.96
Dry mouth 64/250 (25.6) 63/244 (25.8) 0.95
Breathlessness 50/251 (19.9) 57/244 (23.4) 0.55
Sore throat 44/250 (17.6) 51/243 (21.0) 0.20
Fast heart rate 40/251 (15.9) 41/243 (16.9) 0.52
Mood change 33/250 (13.2) 36/243 (14.8) 0.90
Wheeziness 32/251 (12.8) 32/245 (13.1) 0.77
Nausea 26/251 (10.4) 22/242 (9.1) 0.51
Rash 16/249 (6.4) 16/243 (6.6) 0.77
Other 43/240 (17.9) 35/229 (15.3) 0.23
Hypertension specific symptoms
Swelling of legs or ankles 59/251 (23.5) 65/247 (26.3) 0.26
Feeling flushed 40/250 (16.0) 47/243 (19.3) 0.23
Upset stomach 45/252 (17.9) 50/242 (20.7) 0.18
Dizziness 47/251 (18.7) 40/245 (16.3) 0.64
Impotence 37/248 (14.9) 36/234 (15.4) 0.87
table 4 | number of drugs and dose changes in usual care and intervention groups
Drug and dose changes Median (interquartile range) Mean (standard deviation) relative risk* (95% confidence interval)
no of any type of drug change during study period†
Usual care (n=293) 0 (0-1) 0.9 (1.4) 1.0
Intervention (n=283) 1 (0-2) 1.5 (1.7) 1.7 (1.4 to 2.1)
no of dose changes
Usual care (n=293) 0 (0-0) 0.4 (0.7) 1.0
Intervention (n=283) 0 (0-1) 0.7 (1.1) 2.0 (1.5 to 2.7)
no of drug changes
Usual care (n=293) 0 (0-1) 0.5 (1.0) 1.0
Intervention (n=283) 0 (0-1) 0.8 (1.1) 1.5 (1.1 to 1.9)
*Data follow a negative binomial distribution and analysis controls for same factors as primary analysis, and baseline number of drugs.
†Increase in dose or additional drugs.
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people being treated for hypertension in the UK and 
worldwide.
strengths and weaknesses
This was a large trial of a digital intervention in the 
field of hypertension and with follow-up for a year. 
Adequate power existed to detect a difference in blood 
pressure, and over recruitment ensured such an effect 
was not missed. By recruiting from a large number 
of general practices, we ensured generalisability in 
terms of healthcare professionals. However, some 
evidence was found of preferential recruitment of 
those with higher socioeconomic status, although we 
found no evidence that socioeconomic status mediated 
outcomes. Although white ethnicity (94%) appears 
over represented in comparison to the population of 
England and Wales as a whole, this reflects differences 
in ethnicity by age: 95% of those aged 65-69 have 
white ethnicity.33
The mean age of people declining to take part was 
73, and the commonest reason cited was lack of 
internet access, mirroring Ofcom’s latest data showing 
a reduction in computer access by socioeconomic 
status and age.34 While online access is increasing 
year on year in all age groups and societal stratums, 
suggesting this barrier could be reduced in the future, it 
will remain important to better understand barriers to 
uptake by those in more deprived areas.35 Investment 
in specific measures will be needed to enable the most 
vulnerable to engage with digital health initiatives 
and mitigate the risk that digital health contributes 
to a widening of health inequality, particularly as 
deprivation did not modify the effects of intervention.
The study used minimisation to reduce important 
baseline imbalance and this has the potential to 
reduce the effect of randomisation. However, we 
have no evidence that randomisation concealment 
was affected. Similarly imputation can influence 
results, but with high follow-up (89%) and equivalent 
complete case results this seems unlikely.
While prescribing records suggested an increase 
in drug use, and the questionnaires suggested high 
rates of drug adherence, data were not available about 
filling of prescriptions or validated adherence. The best 
measures of drug adherence use electronic systems, 
which were not available for this study. However, 
other work using such methods suggests that self-
monitoring improves adherence.36 Taking into account 
all our observations, it appears likely that increased 
antihypertensive drug use drove lower blood pressure.
The effect size seen in this trial was slightly smaller 
than, but within the confidence intervals of, our trial 
that assessed a similar paper based self-management 
intervention in a similar population. Additionally, the 
upper confidence interval crosses our prespecified 
clinically important level of 5 mm Hg.9 As with our 
previous work, the results at 12 months showed greater 
divergence than at six months, which suggests that the 
intervention might have ongoing impact. We know that 
just under half of patients in the control group reported 
self-monitoring blood pressure during the trial, and that 
these records were used by their general practitioners 
in making treatment decisions; this could reduce the 
effect size, although self-monitoring outside of a more 
complex intervention such as HOME BP has similar 
efficacy to usual care.37 Engagement with the digital 
intervention was high (70% were still monitoring after 
nine months) and equivalent to our previous work, but 
the home monitoring target was not as low as that in 
TASMINH2 (systolic blood pressure 135 v 130 mm Hg) 
owing to changes in national guidance, and this might 
have reduced the effect size.9
The self-monitoring schedule used here was 
developed in our previous self-management work, 
but is different to that recommended in subsequent 
international recommendations.9 10 38 39 However, the 
requirement for 14 readings to be taken per week is 
in line with these recommendations, and recording 
the second of two morning readings each day was 
originally chosen to simplify self-monitoring because 
morning readings are better correlated with stroke 
risk.40
Subgroup analysis suggested a differential effect by 
age, which is important given that such interventions 
have been proposed as particularly relevant to the 
ageing population.4 Participants in the younger half 
table 5 | Patient enablement in usual care and intervention groups
group
no of participants with  
measures at both time points
Mean baseline Pei  
(standard deviation)
Mean 12 month Pei 
(standard deviation)
Difference in Pei at 12 months 
(95% confidence interval)*
Usual care 246 3.0 (1.0) 3.1 (1.1) Reference
Intervention 252 3.1 (1.1) 2.8 (1.0) −0.4 (−0.5 to −0.2)
Modified patient enablement instrument (PEI) is scored from 1 to 7, with lower scores implying higher enablement.26
*Model as per primary outcome but also controlling for baseline PEI.
table 6 | Quality of life measured by using euroQol-5D-5l in usual care and intervention groups. Data are mean (standard deviation) unless stated 
otherwise
group baseline 6 months 12 months
imputed (100 imputations) complete cases
Difference in auc at 6 
months*
Difference in auc at 12 
months*
Difference in auc at 6 
months*
Difference in auc at 12 
months*
Usual care 0.90 (0.13) 0.92 (0.10) 0.90 (0.12) — — — —
Intervention 0.89 (0.14) 0.89 (0.15) 0.90 (0.14) −0.007 (−0.02 to 0.002) 0.002 (−0.007 to 0.01) −0.006 (−0.02 to 0.003) 0.002 (−0.008 to 0.01)
AUC=area under curve.
*Mean difference (95% confidence interval).
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of the age distribution (<67 years) achieved twice the 
overall reduction in systolic blood pressure, and older 
participants (≥67 years) gained no benefit. The effect 
did not seem to be caused by the higher target for people 
older than 80 years, which has not previously been 
observed in other trials of self-monitoring. However, 
too few studies of digital interventions in hypertension 
have been published to assess whether it is a particular 
issue with the type of intervention.7 37 Furthermore, 
the ageing population also influences rising levels 
of multimorbidity, and so the suspicion that those 
with comorbidities gained less from the intervention 
also merits further investigation.41 42 Our process 
evaluation, which is published in detail elsewhere, 
has not found evidence of access or engagement 
problems, or of explanatory characteristics in older 
people or their clinicians, but the results might have 
been confounded by the differential blood pressure 
target for those older than 80 years (145 mm Hg).43 
Given the inclusion criteria included a systolic blood 
pressure of more than 140 mm Hg, older people 
would not have been prompted to change drugs until 
their blood pressure rose 10 mm Hg higher than the 
younger group. Furthermore, we found some evidence 
of increased uptake of physical activity in the younger 
group, which might partly explain the findings (to be 
reported elsewhere).
relation to the literature
We observed an increase in antihypertensive drug 
changes in the intervention group, which suggests 
that the HOME BP intervention led to reduced clinical 
inertia. This phenomenon has been shown to result in 
reduced action by clinicians in the face of evidence, 
in this case of raised blood pressure.44 45 Our previous 
work on self-monitoring and management has also 
resulted in increased use of antihypertensive drugs, 
but the data captured here are more detailed than has 
been previously possible.9 10 46 We used a drug titration 
algorithm that gave clinicians the opportunity to 
develop individual treatment plans for their patients, 
which is in line with national and international 
guidance.38 39 In tandem with reduced clinical inertia, 
self-management in the context of HOME BP improved 
patient enablement, and this might also have mediated 
the effect. However, the behavioural aspects of the 
intervention were less successful and were only taken 
up by a small proportion of participants.
The major advantage of a digital intervention is 
the ability to be deployed at a low marginal cost, and 
the within trial cost effectiveness analysis supports 
this assumption. All training for the intervention was 
delivered online, meaning implementation can also 
be cost effective. This finding is reflected in the cost 
of £11/mm Hg reduction, which compares well with 
£25.66/mm Hg in the HITS trial in Scotland that used 
a propriety telemonitoring system.47 We would expect 
such a blood pressure reduction to lead to a longer 
term impact on cardiovascular events. However, to 
properly assess this impact on cost effectiveness in 
the longer term, additional modelling that takes into 
account these effects with extrapolation to a longer 
time horizon is needed, and we are in the process of 
such work. Previous self-monitoring interventions 
have proven to be cost effective in the long term within 
standard parameters.11 12
Interestingly, the patient enablement instrument 
showed that patients were enabled to be more active 
in controlling their hypertension. Many chose to do 
this through drugs only, whereas a small number 
chose to include behavioural or lifestyle modifications 
as part of blood pressure management. The small 
proportions choosing behavioural support might seem 
counterintuitive, but as has been pointed out before, 
enabled patients do not always make the decisions that 
clinicians or public health physicians would like them 
to.48
Trials of self-monitoring blood pressure appear to 
work best with relatively intensive cointerventions 
(such as telemonitoring, educational advice, or 
pharmacist input) and the current study fits with that 
literature.37 In the context of the current trial, we are 
not able to distinguish the relative importance of the 
different parts of the digital intervention. Relatively 
few studies have been performed that combine self-
monitoring with a digitally delivered cointervention, 
and none has shown a major effect in an adequately 
powered trial over a year.7 The HOME BP trial provides 
evidence that a digitally delivered intervention for 
hypertension can be successful over 12 months, with 
engagement from clinicians and patients.
clinical implications
Surveys suggest that most general practitioners are 
drawing on self-monitoring in their hypertension 
management, and that at least one third of patients 
with hypertension are self-monitoring.49 50 Over and 
above the clinical benefit from the HOME BP digital 
intervention, the ability to manage blood pressure 
remotely at scale has never been so important as 
during the current crisis.13 Therefore, implementation 
of a cost effective digital intervention that leads 
to lower blood pressure would now seem to be 
appropriate. However, such implementation will 
table 7 | costs, systolic blood pressure reduction from baseline, and incremental cost per blood pressure reduction by using bootstrap methods based 
on imputed blood pressure data. Data are mean (95% confidence interval)
group cost (£) incremental cost (£)
systolic blood pressure 
reduction (mm Hg)
incremental systolic blood pressure 
reduction (mm Hg) icer*
Usual care 92 (85 to 99) — 9.8 (8.2 to 11.5) — —
Intervention 130 (122 to 137) 38 (27 to 47) 13.2 (11.7 to 14.8) 3.5 (1.3 to 5.6) 11 (6 to 29)
£1.00=$1.35, €1.10. ICER=incremental cost effectiveness ratio.
*Blood pressure reduction (£/mm Hg).
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not be possible without some consideration of the 
factors that influence successful translation into daily 
practice.51 Some of these factors were successfully 
addressed in the development of HOME BP, which 
used extensive user feedback to ensure that healthcare 
professionals and patients had a shared, positive 
understanding of the aims and likely benefits of HOME 
BP, and perceived it as easy and not onerous to use.16-19 
Achieving clinician buy-in is more likely to occur once 
evidence from trials such as ours is incorporated into 
routine clinical practice guidelines. A key barrier to 
achieving such buy-in and professional usability is 
probably the lack of integration of the HOME BP digital 
intervention into electronic health records. A system 
to allow deployment of proven digital interventions 
within the UK NHS and other health systems is now 
urgently needed. Examples of this are beginning to 
emerge; for example, general practitioners in Scotland 
can now get home blood pressure readings sent to their 
Docman electronic record system (PCTI Solutions, UK), 
although the underlying telemonitoring is SMS based 
and lacks much of the functionality included in the 
HOME BP digital intervention.52 Further work might 
evaluate such implementation to ensure that predicted 
benefits are achieved and to allow further development 
of the intervention, particularly for older people and 
those from more disadvantaged backgrounds.
conclusions
Overall, this digital intervention for the management of 
hypertension that uses self-monitored blood pressure 
and behavioural techniques has led to better control of 
blood pressure than usual care. The HOME BP digital 
intervention, combined with self-monitoring, has the 
potential to provide cost effective support for patients 
and professionals in lowering blood pressure. The 
next step is an implementation strategy to realise such 
benefits for the whole population.
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